Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Roblin

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Journal of Crohn'S & Colitis|January 16, 2015
Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experienceJ Filippi, D Laharie, C Michiels, et al.
Digestive Diseases and Sciences|July 25, 2025
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's DiseaseN Fathallah, M Draullette, J Kirchgesner, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2008
Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experienceA Oussalah, C Laclotte, J-B Chevaux, et al.
La Revue De Medecine Interne|March 3, 2007
[Auto-immune hepatitis and antiphospholipids]S Branger, N Schleinitz, V Veit, et al.
Alimentary Pharmacology & Therapeutics|February 11, 2014
The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel diseaseM Delvincourt, A Lopez, S Pillet, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2018
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factorS Ben-Horin, B Ungar, U Kopylov, et al.
Alimentary Pharmacology & Therapeutics|February 1, 2018
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational studyW Yacoub, N Williet, L Pouillon, et al.
Alimentary Pharmacology & Therapeutics|March 13, 2010
Infliximab for refractory ulcerative proctitisG Bouguen, X Roblin, A Bourreille, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2017
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trialX Roblin, G Boschetti, N Williet, et al.
Alimentary Pharmacology & Therapeutics|July 29, 2008
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppressionL Peyrin-Biroulet, J-F Cadranel, J-B Nousbaum, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Journal of Crohn'S & Colitis|January 16, 2015
Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experienceJ Filippi, D Laharie, C Michiels, et al.
Digestive Diseases and Sciences|July 25, 2025
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's DiseaseN Fathallah, M Draullette, J Kirchgesner, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2008
Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experienceA Oussalah, C Laclotte, J-B Chevaux, et al.
La Revue De Medecine Interne|March 3, 2007
[Auto-immune hepatitis and antiphospholipids]S Branger, N Schleinitz, V Veit, et al.
Alimentary Pharmacology & Therapeutics|February 11, 2014
The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel diseaseM Delvincourt, A Lopez, S Pillet, et al.
Alimentary Pharmacology & Therapeutics|February 16, 2018
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factorS Ben-Horin, B Ungar, U Kopylov, et al.
Alimentary Pharmacology & Therapeutics|February 1, 2018
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational studyW Yacoub, N Williet, L Pouillon, et al.
Alimentary Pharmacology & Therapeutics|March 13, 2010
Infliximab for refractory ulcerative proctitisG Bouguen, X Roblin, A Bourreille, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2017
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trialX Roblin, G Boschetti, N Williet, et al.
Alimentary Pharmacology & Therapeutics|July 29, 2008
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppressionL Peyrin-Biroulet, J-F Cadranel, J-B Nousbaum, et al.
Pageof 9